Demographics and Clinical Characteristics | Number of patients (% of population) |
---|---|
Female, n = 27 | 18 (67%) |
Race, n = 27 | |
 Caucasian | 22 (82%) |
 African-American | 2 (7%) |
 Hispanic | 2 (7%) |
 Asian | 1 (4%) |
Juvenile idiopathic arthritis, n = 17 | 17 (63%) |
 Extended Oligoarticular | 3 (3 ANA+) |
 RF-negative, Polyarticular | 11 (9 ANA+) |
 Enthesitis-related | 1 (HLA-B27 +) |
 Juvenile psoriatic arthritis | 1 (ANA+) |
 Undifferentiated | 1 (ANA+) |
Idiopathic | 7 (26%) |
Sarcoidosis | 1 (4%) |
HLA-B27-associated | 1 (4%) |
Other | 1 (4%) |
Serology, n = 27 | |
 ANA positive | 14 (52%) |
 RF positive | 0 |
 HLA-B27 | 1 (4%) |
 HLA-B51a | 1 (4%) |
Uveitis Laterality, n = 27 | |
 Bilateral | 23 (85%) |
 Unilateral | 4 (15%) |
Uveitis Location, n = 27 | |
 Anterior | 19 (70%) |
 Intermediate | 5 (19%) |
 Anterior Intermediate | 2 (7%) |
 Panuveitis | 1 (4%) |
Age (Mos) of JIA Diagnosis (n = 17) Ave ± SD (median) | 43.6 ± 36.0 (23) |
Age (Mos) of Uveitis Diagnosis (n = 27) Ave ± SD (median) | 86.5 ± 53.5 (76) |
Duration of uveitis (Mos) prior to IFX start date, (n = 27) Ave ± SD (median) | 39.6 ± 36.0 (22) |
Follow-up Duration (Mos) on IFX, (n = 27) Ave ± SD (median) | 41.6 ± 31.2 (35) |
Previous Treatments prior to IFX Startb, n = 27 | |
 Methotrexate (MTX) | 21 (78%) |
 Adalimumab (ADA)c | 14 (52%) |
 Etanercept (ETN) | 1 (4%) |
 Oral prednisone within 2 years prior to IFX start | 7 (65%) |
Indications for IFX | |
 Active uveitis in ≥1 eye pre-IFX [n = 27] | 19 (70%) |
 Active uveitis OR < 0.5+ cell, but > 2 drops PA 1% to control disease [n = 27] | 24 (90%) |
Active JIA (joint disease) [n = 17] | 11 (65%) |